PYC THERAPEUTICS LIMITED (PYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PYC - PYC THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.02
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.45

20 Dec
2024

0.040

OPEN

$1.48

2.84%

HIGH

$1.48

222,106

LOW

$1.37

TARGET
$2.70 86.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PYC: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 9.6 - 11.0 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-9.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx17.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-38.6 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-69.70 %
Return on Invested Capital xxxxxxxxxxxxxxx-69.10 %
Return on Assets xxxxxxxxxxxxxxx-58.76 %
Return on Equity xxxxxxxxxxxxxxx-69.70 %
Return on Total Capital xxxxxxxxxxxxxxx-108.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-38.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx67 M
Price To Book Value xxxxxxxxxxxxxxx6.96

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.3 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx59 M
Research & Development xxxxxxxxxxxxxxx56 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

28/11/2024

1

Speculative Buy

$2.70

86.21%

Bell Potter highlights strong preclinical data for PYC-003, a treatment for autosomal dominant polycystic kidney disease (ADPKD), ahead of its first clinical trials in 2025.

This update provides further conviction to the broker in PYC Therapeutics' asset targeting the most compelling commercial opportunity of all the company's programs.

The Speculative Buy rating and $2.70 target are maintained.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -11.00 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

27/11/2024

1

Buy

$2.40

65.52%

Canaccord Genuity maintains a Buy rating for PYC Therapeutics and a $2.40 target (following a 10:1 share consolidation) supported by positive developments in its VP-001 program for RP11.

The October data update showed statistically significant improvements in low luminance visual acuity (LLVA) at key time points, with reductions in scotomas and enhanced retinal sensitivity. Safety data remained strong, reinforcing confidence in the treatment's potential.

An end-of-Phase-II meeting with the FDA is planned for March/April 2025, with Phase III trials likely commencing mid-2025. The broker expects the trial design to focus on functional endpoints relevant to regulatory approval.

Canaccord highlights the absence of approved treatments for RP11 and anticipates further valuation upside as clinical milestones are achieved. 

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Extra Coverage Research History >

PYC STOCK CHART

FNArena News on PYC

1
Rudi’s View: Banks, WiseTech, Redox & Integral Diagnostics

Dec 19 2024 - Rudi's View
2
Rudi’s View: Best Buys & Smaller Cap Favourites

Dec 12 2024 - Rudi's View
3
Rudi’s View: In Santa We Trust (?)

Dec 05 2024 - Rudi's View
4
Rudi’s View: Trump Beneficiaries & TechOne

Nov 28 2024 - Rudi's View
5
Australian Broker Call *Extra* Edition – Nov 28, 2024

Nov 28 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps